Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation

被引：6
|
作者：
Milone, G. [1 ]
Poidomani, M. [1 ]
Leotta, S. [1 ]
Avola, G. [1 ]
Camuglia, M. G. [1 ]
Privitera, A. [1 ]
Consoli, C. [1 ]
Mercurio, S. [1 ]
Romeo, M. A. [1 ]
Di Marco, A. [1 ]
Di Mercurio, S. [1 ]
Spadaro, A. [1 ]
Palumbo, G. A. [1 ]
Tedeschi, P. [1 ]
机构：
[1] Azienda Osped Policlin Vittorio Emanuele, Osped Ferrarotto, Bone Marrow Transplantat Unit, I-95124 Catania, Italy
来源：
BONE MARROW TRANSPLANTATION | 2012年 / 47卷 / 01期
关键词：
CD34+cell mobilization; AML; hematopoietic transplantation; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; RELAPSE; COLLECTION; EXPRESSION; MORTALITY; CHILDREN; THERAPY;
D O I：
10.1038/bmt.2011.33
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak <= 70 x 10(9)/L (n=48); group B, those having a CD34+ cell peak between 70 and 183 x 10(9)/L (n=24); group C, those having a CD34+ cell peak >183 x 10(9)/L (n=24). Irrespective of post-remission treatment received, group A had a disease free survival (DFS) of 73%, group B a DFS of 51% and group C of 30% (P=0.0003). In intermediate cytogenetic risk patients, those treated by autologous transplantation had a DFS of 68, 33 and 14% in the groups A, B and C, respectively, (P=0.01) whereas after allogeneic transplantation DFS was 87% in group A+B vs 50% in group C (P=0.009). The peak of CD34+ cells in PB, was an independent predictor for DFS in multivariate analysis. Bone Marrow Transplantation (2012) 47, 24-32; doi: 10.1038/bmt.2011.33; published online 14 March 2011
引用
收藏
页码：24 / 32
页数：9
相关论文
共 16 条
  • [1] Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation
    G Milone
    M Poidomani
    S Leotta
    G Avola
    M G Camuglia
    A Privitera
    C Consoli
    S Mercurio
    M A Romeo
    A Di Marco
    S Di Mercurio
    A Spadaro
    G A Palumbo
    P Tedeschi
    Bone Marrow Transplantation, 2012, 47 : 24 - 32
  • [2] Autologous and allogeneic transplantation with peripheral blood CD34+ cells:: a pediatric experience
    Watanabe, T
    Kawano, Y
    Watanabe, A
    Takaue, Y
    HAEMATOLOGICA, 1999, 84 (02) : 167 - 176
  • [3] In AML patients treated by allogeneic hematopoietic transplantation, CD34+supermobilization is a negative prognostic factor
    Avola, Giuseppe
    Camuglia, Maria Grazia
    Milone, Giuseppe
    LEUKEMIA RESEARCH, 2013, 37 (07) : 853 - 854
  • [4] Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics
    Yamasaki, Satoshi
    Yoshimoto, Goichi
    Ogawa, Ryosuke
    Aoki, Kenichi
    Higuchi, Masakazu
    Harada, Naoki
    Arima, Fumito
    Kondo, Seiji
    Matubara, Fujio
    Takahashi, Tsutomu
    Uike, Naokuni
    Miyamoto, Toshihiro
    Okamura, Seiichi
    Akashi, Koichi
    ANNALS OF HEMATOLOGY, 2015, 94 (07) : 1159 - 1165
  • [5] Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics
    Satoshi Yamasaki
    Goichi Yoshimoto
    Ryosuke Ogawa
    Kenichi Aoki
    Masakazu Higuchi
    Naoki Harada
    Fumito Arima
    Seiji Kondo
    Fujio Matubara
    Tsutomu Takahashi
    Naokuni Uike
    Toshihiro Miyamoto
    Seiichi Okamura
    Koichi Akashi
    Annals of Hematology, 2015, 94 : 1159 - 1165
  • [6] High numbers of mobilized CD34+cells collected in AML in first remission are associated with high relapse risk irrespective of treatment with autologous peripheral blood SCT or autologous BMT
    Hengeveld, M.
    Suciu, S.
    Chelgoum, Y.
    Marie, J-P
    Muus, P.
    Lefrere, F.
    Mandelli, F.
    Pane, F.
    Amadori, S.
    Fioritoni, G.
    Labar, B.
    Baron, F.
    Cermak, J.
    Bourhis, J-H
    Storti, G.
    Fazi, P.
    Hagemeijer, A.
    Vignetti, M.
    Willemze, R.
    de Witte, T.
    BONE MARROW TRANSPLANTATION, 2015, 50 (03) : 341 - 347
  • [7] Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation
    Friedman, J
    Lazarus, HM
    Koç, ON
    BONE MARROW TRANSPLANTATION, 2000, 26 (08) : 831 - 836
  • [8] Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation
    J Friedman
    HM Lazarus
    ON Koç
    Bone Marrow Transplantation, 2000, 26 : 831 - 836
  • [9] Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission
    Saraceni, F.
    Bruno, B.
    Lemoli, R. M.
    Meloni, G.
    Arcese, W.
    Falda, M.
    Ciceri, F.
    Alessandrino, E. P.
    Specchia, G.
    Scime, R.
    Raimondi, R.
    Bacigalupo, A.
    Bosi, A.
    Onida, F.
    Rambaldi, A.
    Bonifazi, F.
    Olivieri, A.
    BONE MARROW TRANSPLANTATION, 2017, 52 (01) : 163 - 166
  • [10] Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34+ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation
    Kim, Sang-Mi
    Kim, Hyun-Young
    Kim, Seok Jin
    Jang, Jun Ho
    Kim, Kihyun
    Kim, Won Seog
    Jung, Chul Won
    Cho, Duck
    Kang, Eun-Suk
    JOURNAL OF CLINICAL APHERESIS, 2021, 36 (05) : 737 - 749
12